Literature DB >> 2182695

A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery.

J M Weiler1, M A Gellhaus, J G Carter, R L Meng, P M Benson, R A Hottel, K B Schillig, A B Vegh, W R Clarke.   

Abstract

Protamine sulfate administration may cause life-threatening reactions. We prospectively examined the incidence of immediate adverse reaction after protamine in 243 patients who underwent cardiopulmonary bypass surgery. Twenty-six patients (10.7%) had reactions, and 1.6% had a precipitous drop in blood pressure immediately after protamine administration. Risk factors were previous exposure to protamine, diabetes, history of receiving protamine-containing insulin, and possibly vasectomy. However, neither a positive skin test nor a positive IgE ELISA for antiprotamine antibody predicted that a patient would have a reaction. C4a levels were increased in patients who had reactions as compared with age-, sex-, and cardiac disease-matched patients who did not have reactions, suggesting a role for complement in some reactions. Immediate adverse reactions to protamine are very common, and alternative therapies are urgently needed to eliminate the use of protamine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182695     DOI: 10.1016/0091-6749(90)90189-b

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

1.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.

Authors:  L C Chang; J F Liang; H F Lee; L M Lee; V C Yang
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Prevention of anaphylactic reactions to anaesthetic drugs.

Authors:  Malcolm M Fisher; Gordon S Doig
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Peri-operative anaphylaxis.

Authors:  Linda Nel; Efrem Eren
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Regulation of C5 convertase activity by properdin, factors B and H.

Authors:  J M Weiler
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

5.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.

Authors:  L C Chang; H F Lee; Z Yang; V C Yang
Journal:  AAPS PharmSci       Date:  2001

6.  Immunologic and non-immunologic release of histamine and tryptase from human heart mast cells.

Authors:  V Patella; I Marinò; B Lamparter; A Genovese; M Adt; G Marone
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

7.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

8.  Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair.

Authors:  David A Nelson; Katherine T Nelson; Matthew W Miller; Robert Dupe; Suresh B Chahwala; Anthony Kennedy; Chaman Chander; Theresa W Fossum
Journal:  J Extra Corpor Technol       Date:  2008-06

9.  Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Karuna Chilukuri; Charles A Henrikson; Darshan Dalal; Daniel Scherr; Edwin C MacPherson; Alan Cheng; David Spragg; Saman Nazarian; Sunil Sinha; Ronald Berger; Joseph E Marine; Hugh Calkins
Journal:  J Interv Card Electrophysiol       Date:  2009-03-05       Impact factor: 1.900

10.  Administration of Protamine Through Radial Arterial Access: A Prospective Observational Study.

Authors:  Priyanka Goyal; Sandeep Joshi; Monish S Raut
Journal:  Heart Views       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.